Santen
Text Size
Listen
Santen Global
  • Patients
  • Healthcare Professionals
  • Careers
  • Investors
Listen

Tap on the left to use.

  • Who We Are
    Message
    Message from the CEO
    Santen’s Corporate Philosophy Framework
    Santen’s Corporate Philosophy Framework
    History
    History of Santen
    Corporate Executives
    Corporate Executives
    Corporate Governance
    Corporate Governance
    Policies
    Policies and Statements
    Company Infomation
    Overview / Map
    Global Operation
  • What We Do
    MTP & Santen 2030
    Medium-term Management Plan
    Santen 2030
    Efforts to Enhance Patients' Satisfaction
    Efforts to Enhance Product Safety
    Efforts to Enhance Product Usability
    Efforts to Address Untreated Patients
    Research & Development
    Research & Development
    The Ophthalmic Development Process
    Clinical Trial Information
    Partnering
    Santen's Partnership
    Our Partners
    Partnering Contact
    Production
    Production
    Safety and Quality Assurance
    The Ophthalmic Production Process
    Sales & Marketing
    Sales & Marketing
  • Our Stories
  • Sustainability
    Sustainability
    Our Sustainability Commitment
    Sustainability at Santen
    Social
    Access to Healthcare
    Research & Development in Ophthalmology
    Product Quality & Safety
    Supply Chain
    Human Rights
    Talent
    Digital Transformation (DX)
    Governance
    Corporate Governance
    Compliance
    Ethical Marketing
    Risk Management
    Information Security
    Environment​
    Environmental initiatives
    Measures against Climate Change
    Environmental Load Reduction
    Biodiversity
    Disclosures Based on the TCFD Recommendations
    Inclusion
    Inclusive Society Santen Promotes
    Inclusion Starting from Blind Football
    Together with Society
    With Employees
    Related Information
    Participating in the UN Global Compact
    Social Contribution Activities
    Stakeholder Engagement
    Environment Data (up-to-date)
    Social Data (up-to-date)
    Governance Data (up-to-date)
    GRI Standards Content Index
    Sustainability Library
    External Assessment
  • News
    News
    Show All
    Press Release
    IR News
    Information
  1. HOME
  2. News
  3. 2005

2005 News

  • Press Release
  • IR News
  • Information

Press Release

11.01.2005 Santen Announces Financial Results for the First Six Months ended September 30, 2005[PDF:17KB]
10.12.2005 Santen Receives Manufacturing and Marketing Approval for its Vernal Keratoconjunctivitis Treatment, PAPILOCK Mini Ophthalmic Solution 0.1%[PDF:39KB]
09.29.2005 Santen Establishes Subsidiary in China[PDF:29KB]
09.26.2005 Agreement Concerning CS-011 as Dry Eye Drug Candidate[PDF:18KB]
08.25.2005 Santen to Outsource its Logistics Operations [PDF:17KB]
Press Release

IR News

11.01.2005 Santen Announces Financial Results for the First Six Months ended September 30, 2005[PDF:17KB]
10.12.2005 Santen Receives Manufacturing and Marketing Approval for its Vernal Keratoconjunctivitis Treatment, PAPILOCK Mini Ophthalmic Solution 0.1%[PDF:39KB]
09.29.2005 Santen Establishes Subsidiary in China[PDF:29KB]
09.26.2005 Agreement Concerning CS-011 as Dry Eye Drug Candidate[PDF:18KB]
08.25.2005 Santen to Outsource its Logistics Operations [PDF:17KB]
IR News

Information

Information
News Archive

Official SNS

LinkedIn YouTube
  • Accessibility
  • Terms of Use
  • Privacy Policy
  • Contact
Copyright © 2023 Santen Pharmaceutical Co., Ltd.
All Rights Reserved